- Home
- VXRT vs CABA Comparison
VXRT vs CABA Comparison
Compare VXRT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VXRT
- CABA
- Stock Information
- Founded
- VXRT N/A
- CABA 2017
- Country
- VXRT United States
- CABA United States
- Employees
- VXRT N/A
- CABA N/A
- Industry
- VXRT Biotechnology: Biological Products (No Diagnostic Substances)
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VXRT Health Care
- CABA Health Care
- Exchange
- VXRT Nasdaq
- CABA Nasdaq
- Market Cap
- VXRT 119.0M
- CABA 118.8M
- IPO Year
- VXRT N/A
- CABA 2019
- Fundamental
- Price
- VXRT $0.45
- CABA $2.06
- Analyst Decision
- VXRT Strong Buy
- CABA Strong Buy
- Analyst Count
- VXRT 2
- CABA 9
- Target Price
- VXRT $3.00
- CABA $20.33
- AVG Volume (30 Days)
- VXRT 1.8M
- CABA 2.4M
- Earning Date
- VXRT 05-13-2025
- CABA 05-15-2025
- Dividend Yield
- VXRT N/A
- CABA N/A
- EPS Growth
- VXRT N/A
- CABA N/A
- EPS
- VXRT N/A
- CABA N/A
- Revenue
- VXRT $47,395,000.00
- CABA N/A
- Revenue This Year
- VXRT N/A
- CABA N/A
- Revenue Next Year
- VXRT N/A
- CABA N/A
- P/E Ratio
- VXRT N/A
- CABA N/A
- Revenue Growth
- VXRT 433.43
- CABA N/A
- 52 Week Low
- VXRT $0.29
- CABA $0.99
- 52 Week High
- VXRT $1.07
- CABA $13.50
- Technical
- Relative Strength Index (RSI)
- VXRT 51.74
- CABA 69.08
- Support Level
- VXRT $0.42
- CABA $1.68
- Resistance Level
- VXRT $0.48
- CABA $2.16
- Average True Range (ATR)
- VXRT 0.04
- CABA 0.20
- MACD
- VXRT -0.00
- CABA 0.03
- Stochastic Oscillator
- VXRT 47.06
- CABA 88.89
About VXRT Vaxart Inc
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.